CD4 and neoplasm: Similarly, treatment of melanoma tumor-bearing mice with monoclonal antibody specific for CTLA4 led to the selective depletion of CD4+ Treg cells and a concomitant increase of CD8+ effector T cells within tumor lesions resulting in increased survival28, 29.